Ragni Enrico, Taiana Michela, Visconte Caterina, Kon Elizaveta, Landoni Simona, Colombo Cecilia, Mangiavini Laura, Peretti Giuseppe, de Girolamo Laura
IRCCS Ospedale Galeazzi-Sant'Ambrogio, Laboratorio di Biotecnologie Applicate all'Ortopedia Milano Italy.
IRCCS Humanitas Research Hospital Rozzano Italy.
J Exp Orthop. 2025 May 12;12(2):e70254. doi: 10.1002/jeo2.70254. eCollection 2025 Apr.
Orthobiologics gained popularity for the treatment of musculoskeletal pathologies, including osteoarthritis (OA). Bone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (SVF) were reported to reduce OA symptoms, contributing to the restoration of joint homoeostasis. Variability in production protocols and lack of extensive characterisation hinder a clear indication for the choice of a product over the other. The purpose of this study was to characterise side-by-side BMAC and SVF obtained with the same family of devices, by assessing cell immunophenotype, release of soluble factors and their ability to reduce inflammation in a pathologic in vitro chondrocyte model.
BMAC (iliac crest) and SVF (abdomen liposuction) were obtained from 28 (55 years old ± 8) and 39 patients (56 years old ± 9), with Hy-Tissue BMAC and Hy-Tissue SVF. BMAC/SVF were characterised for cellular content. The number of mesenchymal stromal cells (MSCs) was investigated by flow cytometry (CD45CD31CD34CD90CD105CD146, adipose-MSCs; CD45CD271, bone marrow-MSCs). Two-hundred factors (cytokines, chemokines, receptors, growth factors and inflammatory molecules) were tested by enzyme-linked immunosorbent assay (ELISA). Anti-inflammatory potential was assayed in vitro on interleukin-1 beta (IL1β)-treated chondrocytes by quantitative reverse transcription polymerase chain reaction (qRT-PCR) arrays of 84 genes involved in inflammatory processes.
BMAC had higher concentration for white cells (213x), erythrocytes (49x) and platelets (25x), while the number of MSCs resulted comparable between the two products (1000 cells/mL). One-hundred and twenty-one soluble factors were identified in all analysed samples, with 88 more abundant in BMAC and one in SVF. Gene ontology revealed that the higher concentrated molecules were mainly growth factors and/or involved in differentiation processes. Both orthobiologics reduced inflammation in the in vitro chondrocyte model, with BMAC showing higher efficacy.
Using specific commercial systems, both orthobiologics showed anti-inflammatory effects in vitro. BMAC had higher blood cell and growth factor concentrations than SVF, with greater efficacy. However, variability in commercial systems limits generalisation, requiring further study to draw conclusions when different devices are employed.
NA.
骨科生物制剂在治疗肌肉骨骼疾病（包括骨关节炎（OA））方面越来越受欢迎。据报道，骨髓抽吸浓缩物（BMAC）和脂肪来源的基质血管成分（SVF）可减轻OA症状，有助于恢复关节稳态。生产方案的差异和缺乏广泛的特性描述阻碍了在选择产品时明确选择一种产品优于另一种产品的依据。本研究的目的是通过评估细胞免疫表型、可溶性因子的释放及其在病理性体外软骨细胞模型中减轻炎症的能力，对使用同一类设备获得的BMAC和SVF进行并行特性分析。
使用Hy-Tissue BMAC和Hy-Tissue SVF从28例（55岁±8岁）和39例患者（56岁±9岁）中获取BMAC（髂嵴）和SVF（腹部抽脂）。对BMAC/SVF的细胞含量进行特性分析。通过流式细胞术（CD45、CD31、CD34、CD90、CD105、CD146，脂肪间充质干细胞；CD45、CD271，骨髓间充质干细胞）研究间充质干细胞（MSC）的数量。通过酶联免疫吸附测定（ELISA）检测200种因子（细胞因子、趋化因子、受体、生长因子和炎症分子）。通过对参与炎症过程的84个基因的定量逆转录聚合酶链反应（qRT-PCR）阵列，在白细胞介素-1β（IL1β）处理的软骨细胞上体外测定抗炎潜力。
BMAC中白细胞（213倍）、红细胞（49倍）和血小板（25倍）的浓度更高，而两种产品之间的间充质干细胞数量相当（1000个细胞/毫升）。在所有分析样本中鉴定出121种可溶性因子，其中88种在BMAC中含量更高，1种在SVF中含量更高。基因本体分析表明，浓度较高的分子主要是生长因子和/或参与分化过程。两种骨科生物制剂在体外软骨细胞模型中均能减轻炎症，BMAC显示出更高的疗效。
使用特定的商业系统，两种骨科生物制剂在体外均显示出抗炎作用。BMAC的血细胞和生长因子浓度高于SVF，疗效更佳。然而，商业系统的差异限制了推广，当使用不同设备时需要进一步研究以得出结论。
无。
